Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Multiple Myeloma 23Lymphoma, Mantle-Cell 15Lymphoma, Follicular 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Myeloid, Acute 10Waldenstrom Macroglobulinemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasms, Plasma Cell 7Lymphoma 7Neoplasms 6Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Congenital Abnormalities 4Burkitt Lymphoma 4Sezary Syndrome 3Recurrence 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

Carboplatin 17Paclitaxel 16Radiotherapy 10Taxes 9Cisplatin 8Radiation 7Docetaxel 7Gemcitabine 6Gefitinib 6Bevacizumab 6Erlotinib Hydrochloride 5Radiotherapy, Conformal 3Platinum 3Etoposide 31,2-diaminocyclohexaneplatinum II citrate 3methoxyamine 2Vinorelbine 2Tirapazamine 2Pemetrexed 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2Bortezomib 2veliparib 1vandetanib 1shark cartilage extract 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma of Lung × Bortezomib × Clear all
NCT00118144 2014-08-21

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 7 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
62 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡